Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.38 |
| ▸ | FLT1 | P17948 | 7/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 6/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.33 |
| ▸ | CDK2 | P24941 | 6/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 6/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | KIF5B | P33176 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2024339 | 0.89 | GAA (0.36) | KDRFLT1EGFRGAA | |
| SCHEMBL5474880 | 0.79 | DGAT1 (0.40) | KDREGFRGAARETKIF5B | |
| SCHEMBL5483264 | 0.77 | MAP2K1 (0.46) | KDR | |
| SCHEMBL5478055 | 0.77 | MAP2K1 (0.38) | KDRFLT1 | |
| SCHEMBL3973256 | 0.76 | MAP2K1 (0.34) | KDRFLT1EGFR | |
| SCHEMBL392342 | 0.75 | MAP2K1 (0.47) | KDRFLT1 | |
| SCHEMBL5477603 | 0.75 | MAP2K1 (0.41) | KDRFLT1NUDT1 | |
| SCHEMBL2029046 | 0.74 | ALOX12 (0.42) | KDRFLT1EGFRCDC7CCNE1 | |
| SCHEMBL5481765 | 0.73 | CHRNA7 (0.44) | — | |
| SCHEMBL5485682 | 0.72 | CHRNA7 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093462-A1 | 3-Arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2009-04-09 | — | — | US | claimed |
| EP-1802579-A1 | 3-ARYLAMINO PYRIDINE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2007-07-04 | — | — | EP | claimed |
| WO-2006045514-A1 | 3-ARYLAMINO PYRIDINE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-05-04 | — | — | WO | claimed |
| US-8841459-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2014-09-23 | — | — | US | disclosed |
| US-8841459-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2014-09-23 | — | — | US | disclosed |
| US-20140051686-A1 | 3-Arylamino Pyridine Derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2014-02-20 | — | — | US | disclosed |
| US-20140051686-A1 | 3-Arylamino Pyridine Derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2014-02-20 | — | — | US | disclosed |
| EP-1802579-B1 | Derivatives of 3-arylaminopyridine | MERCK SERONO SA (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8524911-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2013-09-03 | — | — | US | disclosed |
| US-8524911-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2013-09-03 | — | — | US | disclosed |
| US-20120295889-A1 | 3-Arylamino Pyridine Derivatives | MERCK SERONO S.A. (CH) | 2012-11-22 | — | — | US | disclosed |
| US-8198457-B2 | 3-arylamino pyridine derivatives | MERCK SERONO S.A. (CH) | 2012-06-12 | — | — | US | disclosed |
| US-20110224192-A1 | 3-Arylamino Pyridine Derivatives | MERCK SERONO SA (CH) | 2011-09-15 | — | — | US | disclosed |
| US-20110224192-A1 | 3-Arylamino Pyridine Derivatives | MERCK SERONO SA (CH) | 2011-09-15 | — | — | US | disclosed |
| US-7956191-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2011-06-07 | — | — | US | disclosed |
| US-7956191-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2011-06-07 | — | — | US | disclosed |
| US-7956191-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2011-06-07 | — | — | US | disclosed |
| US-20090093462-A1 | 3-Arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2009-04-09 | — | — | US | disclosed |
| US-20090093462-A1 | 3-Arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2009-04-09 | — | — | US | disclosed |
| US-20090093462-A1 | 3-Arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224192-A1 | 3-Arylamino Pyridine Derivatives | MAPK3, BRAF, NRAS | KDR 176/4885FLT1 175/4885EGFR 98/4885 |
| US-20120295889-A1 | 3-Arylamino Pyridine Derivatives | MAPK3, BRAF, NRAS | KDR 176/4885FLT1 175/4885EGFR 98/4885 |
| US-20140051686-A1 | 3-Arylamino Pyridine Derivatives | MAPK3, BRAF, NRAS | KDR 176/4885FLT1 175/4885EGFR 98/4885 |
| US-20090093462-A1 | 3-Arylamino pyridine derivatives | CDK4, BRAF, CDK3 | KDR 174/4885FLT1 186/4885EGFR 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.